Comparison reveals that lipid implants containing Quil-A stimulate CD8+ T cells and IgG production in C57Bl/6 mice, suggesting a superior immunomodulator effect.
The aim of this study was to investigate and compare the immunogenicity of liposome-forming, sustained release lipid implants containing either an α-galactosylceramide (α-GalCer) analogue, imiquimod or Quil-A (QA) as adjuvants. Ovalbumin (OVA) was used as a model antigen. Groups of C57Bl/6 mice were subcutaneously immunised with lipid implants containing one of the adjuvants, or inoculated with OVA in alum. The expansion of CD8+ and CD4+ transgenic T cells was analysed to assess the ability of these implants to stimulate cell-mediated immunity. In addition, the production of OVA-specific IgG antibodies was determined. QA-containing lipid implants were more efficient in the stimulation of CD8+ T cells and IgG antibodies than the two immunomodulators α-GalCer and imiquimod. These results suggest that, using this immunisation protocol and dose of immunomodulators, QA was superior to imiquimod and α-GalCer.
No takes yet. Share an insight, caveat, or question.
Myschik et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: